Ho Wah Genting plans to use up to RM12 million of the placement proceeds to purchase healthcare products and for research and development activities for its healthcare-related business.
Another RM10 million would be used to fully repay a loan from Hong Kong-based Prime King Investment Ltd, which had given Ho Wah Genting a short-term advance for working capital purposes.The group added that up to RM11.77 million of the proceeds would be used for general working capital requirements.Ho Wah Genting expects the private placement to be completed in the first half of 2021.
US FDA APPROVED HWGB’S JV PARTNER, EBI TO CONDUCT THE 2ND STAGE OF PHASE 4 CLINICAL TRIAL FOR COVID-19 VACCINATION
Aint sure it would benefit to the company or not; if the research is successful then i would say we could be benefit from it so much else it is just another money burning research
Right now any vaccines that can get FDA approval will be a huge help globally. WHO too will continue to add more vaccines on their approval list (read the news on the Chinese vaccines getting WHO approval) as well because globally there is a shortage as countries rush to get vaccine supply to get out of the current pandemic challenges.
hi guys, may i know the exercise price is 0.32, and the ex date is 15/3/21, so if hwg mother stays above 0.32, we will automatically get mother share with the quantity we bought ?
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
damiel
78 posts
Posted by damiel > 2021-01-13 11:37 | Report Abuse
Ho Wah Genting plans to use up to RM12 million of the placement proceeds to purchase healthcare products and for research and development activities for its healthcare-related business.